Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections

References

• Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev 2002; 15(4):631-46; PMID:12364373; http://dx.doi.org/10.1128/CMR.15.4.631-646.2002
   PubMed Web of Science ®Google Scholar
• Wayne Conlan J, Oyston PC. Vaccines against Francisella tularensis. Ann N Y Acad Sci 2007; 1105:325-50; PMID:17395730; http://dx.doi.org/10.1196/annals.1409.012
   PubMedGoogle Scholar
• El Sahly HM, Atmar RL, Patel SM, Wells JM, Cate T, Ho M, Guo K, Pasetti MF, Lewis DE, Sztein MB, et al . Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 2009; 27(36):4905-11; PMID:19567246; http://dx.doi.org/10.1016/j.vaccine.2009.06.036
   PubMed Web of Science ®Google Scholar
• Eneslätt K, Rietz C, Rydén P, Stöven S, House RV, Wolfraim LA, Tärnvik A, Sjöstedt A. Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis. Eur J Immunol 2011; 41(4):974-80; http://dx.doi.org/10.1002/eji.201040923
   PubMed Web of Science ®Google Scholar
• Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum Vaccin 2011; 7(10):999-1011; PMID:21941090; http://dx.doi.org/10.4161/hv.7.10.16369
   PubMed Web of Science ®Google Scholar
• Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67(3):351-68; PMID:17335295; http://dx.doi.org/10.2165/00003495-200767030-00003
   PubMed Web of Science ®Google Scholar
• Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008; 26(8):1011-24; PMID:18242792; http://dx.doi.org/10.1016/j.vaccine.2007.12.007
   PubMedGoogle Scholar
• Maier TM, Havig A, Casey M, Nano FE, Frank DW, Zahrt TC. Construction and characterization of a highly efficient Francisella shuttle plasmid. Appl Environ Microbiol 2004; 70(12):7511-9; PMID:15574954; http://dx.doi.org/10.1128/AEM.70.12.7511-7519.2004
   PubMed Web of Science ®Google Scholar
• Zaide G, Grosfeld H, Ehrlich S, Zvi A, Cohen O, Shafferman A. Identification and characterization of novel and potent transcription promoters of Francisella tularensis. Appl Environ Microbiol 2011; 77(5):1608-18; PMID:21193666; http://dx.doi.org/10.1128/AEM.01862-10
   PubMedGoogle Scholar
• Castric PA, Sidberry HF, Sadoff JC. Cloning and sequencing of the Pseudomonas aeruginosa 1244 pilin structural gene. Mol Gen Genet 1989; 216(1):75-80; PMID:2499765; http://dx.doi.org/10.1007/BF00332233
   PubMedGoogle Scholar
• Sugawara E, Nestorovich EM, Bezrukov SM, Nikaido H. Pseudomonas aeruginosa porin OprF exists in two different conformations. J Biol Chem 2006; 281(24):16220-9; PMID:16595653; http://dx.doi.org/10.1074/jbc.M600680200
   PubMedGoogle Scholar
• Verma A, Arora SK, Kuravi SK, Ramphal R. Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response. Infect Immun 2005; 73(12):8237-46; PMID:16299320; http://dx.doi.org/10.1128/IAI.73.12.8237-8246.2005
   PubMedGoogle Scholar
• Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 2011; 29(11):2131-9; PMID:21215829; http://dx.doi.org/10.1016/j.vaccine.2010.12.087
   PubMed Web of Science ®Google Scholar
• Kao DJ, Churchill ME, Irvin RT, Hodges RS. Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of Pseudomonas aeruginosa. J Mol Biol 2007; 374(2):426-42; PMID:17936788; http://dx.doi.org/10.1016/j.jmb.2007.09.032
   PubMedGoogle Scholar
• Faezi S, Safarloo M, Amirmozafari N, Nikokar I, Siadat SD, Holder IA, Mahdavi M. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection. APMIS 2014; 122(2):115-27; PMID:23758581; http://dx.doi.org/10.1111/apm.12101
   PubMedGoogle Scholar
• Faridmoayer A, Fentabil MA, Mills DC, Klassen JS, Feldman MF. Functional characterization of bacterial oligosaccharyltransferases involved in O-linked protein glycosylation. J Bacteriol 2007; 189(22):8088-98; PMID:17890310; http://dx.doi.org/10.1128/JB.01318-07
   PubMed Web of Science ®Google Scholar
• Horzempa J, Tarwacki DM, Carlson PE, Robinson CM, Nau GJ. Characterization and application of a glucose-repressible promoter in Francisella tularensis. Appl Environ Microbiol 2008; 74(7):2161-70; PMID:18245238; http://dx.doi.org/10.1128/AEM.02360-07
   PubMedGoogle Scholar
• Horzempa J, Carlson PE, O'Dee DM, Shanks RM, Nau GJ. Global transcriptional response to mammalian temperature provides new insight into Francisella tularensis pathogenesis. BMC Microbiol 2008; 8:172; PMID:18842136; http://dx.doi.org/10.1186/1471-2180-8-172
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012; 209(7):1273-87; PMID:22734046; http://dx.doi.org/10.1084/jem.20120033
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Rao J, Harcher K, Zaidi TS, Gardner J, Neely AN, Pier GB, Goldberg JB. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 2007; 104(11):4624-9; PMID:17360574; http://dx.doi.org/10.1073/pnas.0608657104
   PubMedGoogle Scholar
• Horzempa J, Held TK, Cross AS, Furst D, Qutyan M, Neely AN, Castric P. Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection. Clin Vaccine Immunol 2008; 15(4):590-7; PMID:18272666; http://dx.doi.org/10.1128/CVI.00476-07
   PubMedGoogle Scholar
• Cunningham AL, Dang KM, Yu JJ, Guentzel MN, Heidner HW, Klose KE, Arulanandam BP. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB. Vaccine 2014; 32(40):5234-40; PMID:25050972; http://dx.doi.org/10.1016/j.vaccine.2014.07.038
   PubMed Web of Science ®Google Scholar
• Tani C, Inoue K, Tani Y, Harun-ur-Rashid M, Azuma N, Ueda S, Yoshida K, Maeda I. Sensitive fluorescent microplate bioassay using recombinant Escherichia coli with multiple promoter-reporter units in tandem for detection of arsenic. J Biosci Bioeng 2009; 108(5):414-20; PMID:19804866; http://dx.doi.org/10.1016/j.jbiosc.2009.05.014
   PubMedGoogle Scholar
• McWhinnie RL, Nano FE. Synthetic promoters functional in Francisella novicida and Escherichia coli. Appl Environ Microbiol 2014; 80(1):226-34; PMID:24141126; http://dx.doi.org/10.1128/AEM.02793-13
   PubMed Web of Science ®Google Scholar
• LoVullo ED, Miller CN, Pavelka MS, Kawula TH. TetR-based gene regulation systems for Francisella tularensis. Appl Environ Microbiol 2012; 78(19):6883-9; PMID:22820330; http://dx.doi.org/10.1128/AEM.01679-12
   PubMedGoogle Scholar
• Horzempa J, Shanks RM, Brown MJ, Russo BC, O'Dee DM, Nau GJ. Utilization of an unstable plasmid and the I-SceI endonuclease to generate routine markerless deletion mutants in Francisella tularensis. J Microbiol Methods 2010; 80(1):106-8; PMID:19879904; http://dx.doi.org/10.1016/j.mimet.2009.10.013
   PubMedGoogle Scholar
• LoVullo ED, Sherrill LA, Perez LL, Pavelka MS. Genetic tools for highly pathogenic Francisella tularensis subsp. tularensis. Microbiology 2006; 152(Pt 11):3425-35; PMID:17074911; http://dx.doi.org/10.1099/mic.0.29121-0
   PubMedGoogle Scholar
• LoVullo ED, Sherrill LA, Pavelka MS. Improved shuttle vectors for Francisella tularensis genetics. FEMS Microbiol Lett 2009; 291(1):95-102; PMID:19067747; http://dx.doi.org/10.1111/j.1574-6968.2008.01440.x
   PubMedGoogle Scholar
• LoVullo ED, Molins-Schneekloth CR, Schweizer HP, Pavelka MS. Single-copy chromosomal integration systems for Francisella tularensis. Microbiology 2009; 155(Pt 4):1152-63; PMID:19332817; http://dx.doi.org/10.1099/mic.0.022491-0
   PubMedGoogle Scholar
• Kalivoda EJ, Horzempa J, Stella NA, Sadaf A, Kowalski RP, Nau GJ, Shanks RM. New vector tools with a hygromycin resistance marker for use with opportunistic pathogens. Mol Biotechnol 2011; 48(1):7-14; PMID:20972648; http://dx.doi.org/10.1007/s12033-010-9342-x
   PubMedGoogle Scholar
• Jia Q, Bowen R, Sahakian J, Dillon BJ, Horwitz MA. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge. Infect Immun 2013; 81(5):1550-61; PMID:23439306; http://dx.doi.org/10.1128/IAI.01013-12
   PubMedGoogle Scholar
• Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 2014; 58(8):4384-91; PMID:24841258; http://dx.doi.org/10.1128/AAC.02643-14
   PubMed Web of Science ®Google Scholar
• Schmitt DM, O'Dee DM, Brown MJ, Horzempa J, Russo BC, Morel PA, Nau GJ. Role of NK cells in host defense against pulmonary type A Francisella tularensis infection. Microbes Infect 2013; 15(3):201-11; PMID:23211929; http://dx.doi.org/10.1016/j.micinf.2012.11.008
   PubMedGoogle Scholar
• DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004; 72(12):7012-21; PMID:15557624; http://dx.doi.org/10.1128/IAI.72.12.7012-7021.2004
   PubMedGoogle Scholar